GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genotech Corp (XKRX:066830) » Definitions » Debt-to-EBITDA

Genotech (XKRX:066830) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Genotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩0 Mil. Genotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩0 Mil. Genotech's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩126 Mil. Genotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genotech's Debt-to-EBITDA or its related term are showing as below:

During the past 9 years, the highest Debt-to-EBITDA Ratio of Genotech was 92.21. The lowest was -32.51. And the median was 1.35.

XKRX:066830's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.41
* Ranked among companies with meaningful Debt-to-EBITDA only.

Genotech Debt-to-EBITDA Historical Data

The historical data trend for Genotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genotech Debt-to-EBITDA Chart

Genotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 8.29 0.53 0.45 0.34 -

Genotech Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only 8.29 0.53 0.45 0.34 -

Competitive Comparison of Genotech's Debt-to-EBITDA

For the Biotechnology subindustry, Genotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genotech's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genotech's Debt-to-EBITDA falls into.



Genotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 126.353
=0.00

Genotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 126.353
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2023) EBITDA data.


Genotech  (XKRX:066830) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genotech Business Description

Traded in Other Exchanges
N/A
Address
26-69, Gajeongbuk-ro, Yuseong-gu, Daejeon, KOR, 305-343
Genotech Corp is engaged in manufacturing basic pharmaceutical substances and biological agents.

Genotech Headlines

No Headlines